top of page

Advocates for the Prevention of HIV in Africa

Meet 4 people who got the HIV prevention jab

Apha News
11 minutes ago
1 min read

A recent article produced by the Bhekisisa Centre for Health Journalism sheds light on the real-world impact of South Africa’s rollout of long-acting injectable HIV pre-exposure prophylaxis (PrEP), Lenacapavir.


The feature profiling four individuals who have received the twice-yearly HIV pr

evention jab highlights how this medical innovation is changing the landscape of HIV prevention. For many, injectable PrEP offers a discreet, convenient, and highly effective alternative to daily oral tablets - eliminating the stigma, inconvenience, and routine pill burden often associated with daily PrEP regimens.


Key takeaways from the individual stories in the article include:

  • Personalised Experiences: First-hand accounts from recipients detailing their decisions to switch to injectable PrEP and how it fits into their daily lives.

  • Overcoming Pill Fatigue: How long-acting options make adherence easier, particularly for key populations and young individuals.

  • Access & Implementation: Insights into the accessibility of the jab across clinics and healthcare facilities as public health programs continue expanding access.


For more insights, read the four women’s full first-hand accounts on one of the resources below:

 
 
 

Comments

bottom of page